(Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced positive interim results from two Phase 1b studies of its investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback